American Heart Association

American Heart Association

February 14, 2016
6 min watch
Save

VIDEO: New prevention research buoys field in fight against CHD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO, Fla. — Sameer Bansilal, MD, MS, of the Icahn School of Medicine at Mount Sinai, discusses the tasks looming ahead for cardiologists in the arena of CHD in context of top research presented at the annual American Heart Association Scientific Sessions.

Against a backdrop of the Google-AHA joint initiative, Bansilal emphasizes the call: “It is for one team with one vision and a $50 million grant to work toward a simple proposal to prevent and cure disease.”

He discusses the “tremendous finding” on intensive BP management from the SPRINT study, which he said “really does change the practice pattern pretty much immediately.”

Bansilal highlights promising results from the PEGASUS-TIMI 54 study focusing on the long-term tolerability of ticagrelor (Brilinta, AstraZeneca), as well as positive ischemic risk outcomes seen with a novel dual antiplatelet therapy score that has “huge implication for clinicians.”

He also touches on conclusions on bypass surgery from a mixed analysis of the BARI 2D, COURAGE and FREEDOM trials, specifically looking at patients with diabetes and multivessel disease.

Overall, he said the meeting got attendees “riled up about the concept of coronary disease and prevention.”